|
#
|
Title
|
Authors
|
Affiliations
|
Keywords
|
|
P160
|
Chimeric Antigen Receptors Interact With Multiple Endogenous T Cell Proteins And Induce Tonic Signaling Through Phosphorylation Of Endogenous CD3ζ
|
Maria C. Ramello1, Ismahène Benzaid1, Brent M. Kuenzi1, Maritza Lienlaf1, Wendy M. Kandell1, Daniel N. Santiago1, Mibel Pabón-Saldaña1, Lancia Darville1, Bin Fang1, Uwe Rix1, Sean Yoder1, Anders Berglund1, John Koomen1, Eric Haura1, Daniel Abate-Daga1
|
1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
|
Adoptive immunotherapy | Bioinformatics | Systems biology | CAR T cells | Gene expression | T cell | Solid tumors
|
|
P161
|
Engineering adoptive T cell therapy for efficacy in ovarian cancer
|
Kristin Anderson1, Breanna Bates1, Edison Chiu2, Nicolas Garcia1, Christopher Morse1, Philip Greenberg2
|
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA 2University of Washington, Seattle, WA, USA
|
Adoptive immunotherapy | Tumor microenvironment | Solid tumors | T cell | Immune suppression | Tumor antigens
|
|
P162
|
Preclinical evaluation of BCMA-specific TAC receptor-engineered T cells for multiple myeloma
|
Ksenia Bezverbnaya1, Craig Aarts1, Christopher Helsen1, Galina Denisova1, Arya Afsahi1, Carole Evelegh1, Derek Cummings1, Jonathan Bramson1
|
1McMaster University, Hamilton, ON, Canada
|
Adoptive immunotherapy | Targeted therapy | T cell
|
|
P163
|
Enhanced functional profile of CAR-T cells generated in the presence of mTOR kinase inhibitor
|
Archana Brahmandam1, David Swart1, Alex Baturevych1, Ron Hause1, Ruth Salmon1, Jason D. Fontenot1, Lucas J. Thompson1
|
1Juno Therapeutics, Inc., Seattle, WA, USA
|
Adoptive immunotherapy | T cell | T cell lineages | Metabolism | Cytokine | CAR T cells | Targeted therapy
|
|
P164
|
A Temporal and Spatial analytical system to measure CAR-T cell function
|
Ana Castano1, Angela Boroughs1,2, Marcela Maus1,2
|
1Massachusetts General Hospital, Charlestown, MA, USA 2Harvard Medical School, Charlestown, MA, USA
|
Costimulation | Tumor microenvironment | Regulatory T cell (Treg) | Solid tumors | CAR T cells
|
|
P165
|
High throughput label-free impedance-based technology for kinetic in vitro functional potency assessment of immune cell-mediated cytolysis and immune checkpoint modulation
|
Fabio Cerignoli1, Biao Xi1, Garret Guenther1, Lincoln Muir1, Brandon Lamarche1, Nikhil Mittal1, David Untiet1, Yama Abassi1
|
1ACEA Biosciences, San Diego, CA, USA
|
Antibody | CAR T cells | Checkpoint blockade | B cell | Immune adjuvant | Immune suppression | NK/NK T cell | Solid tumors | Leukemia/Lymphoma | Immune monitoring
|
|
P166
|
H3.3K27M mutation-derived novel neoantigen – characterization of the HLA-A2-binding epitope and a specific T cell receptor for development of T cell-based immunotherapy
|
Zinal Chheda1, Gary Kohanbash1, Kaori Okada1, Naznin Jahan1, John Sidney2, Matteo Pecoraro3, Diego Carrera1, Shruti Shrivastav1, Shuming Liu1, Sabine Mueller1, Ian Pollack5, Raja Rajalingam1, Angel Carcaboso6, Matthias Mann4, Alessandro Sette7, Yafei Hou1, Hideho Okada1
|
1University of California, San Francisco, San Francisco, CA, USA 2La Jolla Institute, La Jolla, CA, USA 3Max Planck Institute of Biochemistry, Martinsried, Germany 4Max-Planck-Institut für Biochemie, Martinsried, Germany 5University of Pittsburgh School of Medicine, Pittsburgh, PA, USA 6Institut de Recerca Sant Joan de Deu, Barcelona, Spain 7La Jolla Institute For Allergy and Immunology, La Jolla, CA, USA
|
Tumor antigens | Adoptive immunotherapy | Pediatric tumors | T cell | Neoantigens | Solid tumors
|
|
P167
|
Translation of highly functional CMV-induced “adaptive” NK cells to treat cancer.Translation of highly functional CMV-induced “adaptive” NK cells to treat cancer
|
Sarah Cooley1, Frank Cichocki1, Bob Valemehr2, David McKenna1, Jeffrey Miller1
|
1University of Minnesota, Minneapolis, MN, USA 2FATE Therapeutics, San Diego, CA, USA
|
Adoptive immunotherapy | NK/NK T cell | Clinical trial | Cytokine | Leukemia/Lymphoma | Clinical study
|
|
P168
|
CBLB gene editing potentiates the effector function of tumor-targeted engineered-TCR human T cells
|
Andreia S. Da Costa1, Alexandra Croft1, Vidya Dhanapal2, Michael Dinsmore2, Georgia Giannoukos2, Kiran Gogi2, Gregory Gotta2, Fred Harbinski2, Christopher J. Wilson2, G. Grant Welstead2, Jason D. Fontenot1
|
1Juno Therapeutics, Inc, Seattle, WA, USA 2Editas Medicine, Cambridge, MA, USA
|
Adoptive immunotherapy | Costimulation | T cell | Solid tumors | Targeted therapy
|
|
P169
|
Mass-Spectrometry-Guided Target Selection and TCR Profiling: Towards the Development of Safer TCR-Engineered T Cell Therapies
|
Thorsten Demberg1, Mamta Kalra1, Leonie Alten2, Amir Alpert1, Sebastian Bunk2, Jens Fritsche2, Oliver Schoor2, Dominik Maurer2, Ali Mohammed1, Yannick Bulliard1, Harpreet Singh1, Carsten Reinhardt3, Toni Weinschenk2, Steffen Walter1
|
1Immatics US Inc., Houston, TX, USA 2Immatics Biotechnologies GmbH, Tuebingen, Germany 3Immatics Biotechnologies GmbH, Martinsried, Germany
|
Adoptive immunotherapy | T cell | Tumor antigens | Targeted therapy
|
|
P170
|
Exploiting CD4 T cells for adoptive cell therapy in cancer
|
Pierre Dillard1, Marit Myrhe1, Nadia Mensali1, Sylvie Pollmann1, Gunnar Kvalheim1, Gustav Gaudernack1, Sebastien Wälchli1, Else Marit Inderberg1
|
1OUS-Radiumhospital Oslo Cancer Cluster incubator (OCCi), Oslo, Norway
|
Adoptive immunotherapy | T cell lineages | Targeted therapy | T cell | Solid tumors
|
|
P171
|
Preclinical Evaluation of Mesothelin-specific T Cell Receptor (TCR) Fusion Constructs (TRuC™s) Utilizing the Signaling Power of the Complete TCR Complex: A New Opportunity for Solid Tumor Therapy
|
Jian Ding1, Ekta Patel1, Patrick Tavares1, Justin Quinn1, Rashmi Choudhary1, Bonnie Le1, Olga Kiner1, Qi Wei1, Solly Weiler1, Patrick Baeuerle1, Robert Hofmeister1
|
1TCR2 Therapeutics, Cambridge, MA, USA
|
Adoptive immunotherapy | T cell | Solid tumors | CAR T cells
|
|
P172
|
iRGD enhances T cells infiltration and augments response to PD-1 gene knockout immunotherapy in gastric cancer
|
baorui liu1, naiqing ding1
|
1The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China
|
Adoptive immunotherapy | Targeted therapy | Checkpoint blockade | Solid tumors | T cell
|
|
P173
|
Mass cytometry based immunophenotyping of tumor-reactive T cells in human cancer reveals subpopulations with coordinate inhibitory molecule expression
|
Monika Aleksandra Eiva1, Jessica Ann Chacon1, Tori Yamamoto1, Thomas Garrabrant1, Gabor Kari1, Andrew Best1, Qunrui Ye1, Daniel J Powell1
|
1University of Pennsylvania, Philadelphia, PA, USA
|
Biomarkers | Checkpoint blockade | Immune suppression | Cytokine | T cell | Tumor infiltrating lymphocytes (TILs) | Solid tumors | Antibody
|
|
P174
|
Removal of double stranded RNA using a novel method with RNaseIII produces robust mRNA chimeric antigen receptor T cell therapy
|
Jessica Foster1, Namrata Choudhari1, Jessica Perazzelli1, Angela Waanders1, Julie Storm1, Ted Hofmann1, Payal Jain1, Phillip Storm1, Stephan Grupp1, Katalin Kariko2, Adam Resnick1, David Barrett1
|
1The Children's Hospital of Philadelphia, Philadelphia, PA, USA 2BioNTech RNA Pharmaceuticals, Mainz, Germany
|
CAR T cells | Leukemia/Lymphoma | Pediatric tumors
|
|
P175
|
A rapid and streamlined method for the culture of Tumor Infiltrating Lymphocytes (TIL) from melanoma tumor fragments
|
Nermin Gerges1, Shari Pilon-Thomas1, Amod Sarnaik1, John Mullinax1, Cheryl Cox1, Sandra Gonzalez-Rivera1, Ludivina Lay1, Linda Kelley1
|
1Moffitt Cancer Center, Tampa, FL, USA
|
Adoptive immunotherapy | Tumor infiltrating lymphocytes (TILs)
|
|
P176
|
AdoptCell®-NK: Ex vivogeneration of highly purified and activated natural killer cells from human peripheral blood in accordance with GMP/GCTP for clinical studies
|
Yui Harada1, Yoshikazu Yonemitsu1
|
1Kyushu University, Fukuoka, Japan
|
NK/NK T cell | Adoptive immunotherapy
|
|
P177
|
Engineering Artificial Lymph Nodes for Immunotherapy
|
John Hickey1, Hai-Quan Mao2, Jonathan Schneck1
|
1Johns Hopkins School of Medicine, Baltimore, MD, USA 2Johns Hopkins University, Baltimore, MD, USA
|
Adoptive immunotherapy | Antigen presenting cells | T cell | Immune suppression | Costimulation | Dendritic cell | Tumor microenvironment | Tumor antigens | Targeted therapy | Tumor infiltrating lymphocytes (TILs)
|
|
P178
|
Combined killing of cancer cells and cross presentation of tumor antigen by Vγ9Vδ2 T cells
|
Gitte Holmen Olofsson1, Manja Idorn1, Elfriede Nössner2, Ramona Schenker2, Reno Debets3, Özcan Met1, Per thor Straten1
|
1Center for Cancer immunotherapy (CCIT), Herlev, Denmark 2Institute for Molecular Immunology, München, Germany 3Erasmus MC Cancer Institute, Rotterham, Netherlands
|
Antigen presenting cells | Adoptive immunotherapy | T cell
|
|
P179
|
NKG2D ligand–inducing immune therapy plus NKG2D+CD8+ T cell therapy overcomes chemoresistance in tumors
|
Jiemiao Hu1, Izhar Batth1, Chantale Bernatchez1, Xueqing Xia1, Patrick Hwu1, Richard Gorlick1, Shulin Li1
|
1The University of Texas MD Anderson Cancer Center, Houston, TX, USA
|
Adoptive immunotherapy | Tumor microenvironment | Chemokine | Cytokine | T cell | Solid tumors | Tumor infiltrating lymphocytes (TILs)
|
|
P180
|
Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model.
|
Manja Idorn1, Signe Koggersbøl Skadborg1, Lauge Kellerman2, Hólmfrídur Rósa Halldórsdóttir1, Gitte Holmen Olofsson1, Özcan Met1, Per thor Straten1
|
1Center for Cancer Immune Therapy, Herlev Gentofte Hospital, Herlev, Denmark 2Herlev Hospital, Herlev, Denmark
|
Adoptive immunotherapy | Chemokine | T cell | Tumor infiltrating lymphocytes (TILs) | Solid tumors
|
|
P181
|
Production of site-specific Allogeneic CD19 CAR-T Cells by CRISPR-Cas9 for B-Cell Malignancies.
|
Zinkal Padalia1, Ashley Porras1, Dakai Mu1, Min Jin Lee1, Ying Zhang1, Elaine Huang1, Ashley Maillet1, Jeffrey Li1, Matthias John1, Lawrence Klein1, Sven Ante Lundberg1, Seshi Police1, Jonathan Terrett1, Demetrios Kalaitzidis1
|
1CRISPR Therapeutics, Cambridge, MA, USA
|
Leukemia/Lymphoma | Targeted therapy | Tumor antigens | B cell | CAR T cells | T cell | Adoptive immunotherapy
|
|
P182
|
Development of chemically defined medium for ex vivoexpansion of Natural Killer cells
|
Jessie Kinjo1, Vanda S. Lopes1, Jessie H.-T. Ni1
|
1Irvine Scientific, Santa Ana, CA, USA
|
NK/NK T cell | Clinical study | Adoptive immunotherapy | Targeted therapy
|
|
P183
|
Stem cell differentiation towards tumor-recognizing CD4 T cells provides robust anti-tumor effects in combination with CD8-TCR-T cell therapy
|
Richard Koya1, Junko Matsuzaki1, Takemasa Tsuji1, Satoko Matsueda1, Thinle Chodon1, Kunle Odunsi1
|
1Roswell Park Cancer Institute, Buffalo, NY, USA
|
Adoptive immunotherapy | Stem cell/cancer-initiating cell | T cell | Solid tumors | Tumor infiltrating lymphocytes (TILs) | T cell lineages | Tumor antigens | CAR T cells
|
|
P184
|
Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma
|
Veronika Kremer1, Maarten Ligtenberg2, Rosa Zendehdel1, Christina Seitz1, Annet Duivenvoorden1, Erik Wennerberg3, Eugenia Colón4, Ann-Helén Scherman Plogell4, Andreas Lundqvist1
|
1Karolinska Institutet, Stockholm, Sweden 2The Netherlands Cancer Institute, Amsterdam, Netherlands 3Weill Cornell Medicine, New York, NY, USA 4Stockholm South General Hospital, Stockholm, Sweden
|
Adoptive immunotherapy | Chemokine | NK/NK T cell | Solid tumors
|
|
P185
|
A novel chimeric T cell receptor that operates through the endogenous TCR diverges in biology from conventional CAR T cells
|
Vivian Lau1, Ksenia Bezverbnaya1, Alina Lelic1, Anna Dvorkin-Gheva1, Joanne Hammill1, Arya Afsahi1, Galina Denisova1, Christopher Helsen1, Jonathan Bramson1
|
1McMaster University, Hamilton, ON, Canada
|
Adoptive immunotherapy | CAR T cells | T cell
|
|
P186
|
Molecular nanomachines for in situ reprogramming of innate immunity
|
Sandro Matosevic1
|
1Purdue University, West Lafayette, IN, USA
|
Adoptive immunotherapy | Tumor microenvironment | NK/NK T cell | Targeted therapy
|
|
P187
|
Efficient Non-Small Lung Cancer targeted therapy with TCR-T cell transfer engineered for TGFβ blockade
|
Satoko Matsueda1, Adekunle Odunsi1, Richard Koya1
|
1Roswell Park Cancer Institute, Buffalo, NY, USA
|
Adoptive immunotherapy | Tumor infiltrating lymphocytes (TILs) | Tumor microenvironment | Tumor antigens | T cell | Solid tumors
|
|
P188
|
A Universal Killer T-Cell for Adoptive Cell Therapy of Cancer
|
Nadia Mensali1, Pierre Dillard1, June H Myklebust1, Michael Hebeisen3, Gjertrud Skorstad1, Marit Renee Myhre1, Anne Fane1, Gustav Gaudernack2, Gunnar Kvalheim1, Else Marit Inderberg1, Sebastien Walchli1
|
1Oslo University Hospital OUS-Radiumhospital, Oslo, Norway 2Oslo University Hospital, Oslo, Norway 3Lausanne University Hospital, Lausanne, Switzerland
|
Adoptive immunotherapy | Targeted therapy | Tumor antigens | T cell | NK/NK T cell | Solid tumors
|
|
P189
|
Cytotoxic dendritic cells have efficient anti-tumor capacity of in a murine T cell lymphoma model
|
Jürgen Müller1, Thomas Waldmann1, Sigrid Dubois1
|
1NIH, Bethesda, MD, USA
|
Dendritic cell | Immune toxicity | Leukemia/Lymphoma
|
|
P190
|
Patient Specific Automated Dendritic Cell Generation in a Closed System
|
Andrew Kozbial1, Lekhana Bhandary1, Christopher Eickhoff2, Bradley Collier1, Daniel Hoft2, Shashi Murthy1
|
1Northeastern University, Boston, MA, USA 2Saint Louis University, St Louis, MO, USA
|
Antigen presenting cells | Adoptive immunotherapy | Dendritic cell | Neoantigens | Vaccine | Monocyte/Macrophage
|
|
P191
|
Limiting antigen escape in multiple myeloma by dual antigen-targeting of BCMA and TACI using the natural ligand APRIL
|
Maria Ormhoj1, Felipe Bedoya2, Irene Scarfò2, Benjamin Kleinstiver2, J. Keith Joung2, Torben Barington3, Marcela Maus2
|
1University of Southern Denmark and Massachusetts General Hospital Cancer Center, Harvard Medical School, Brookline, MA, USA 2Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA 3Odense University Hospital, University of Southern Denmark, Odense, Denmark
|
Adoptive immunotherapy | Targeted therapy | T cell | CAR T cells
|
|
P192
|
Oncolytic Viruses Effectively Deliver Chimeric Antigen Receptor Targets to Triple Negative Breast Cancers
|
Anthony Park1, Saul Priceman1, Stephen Forman1, Yuman Fong2, Nanhai Chen2, Dileshni Tilakawardane1, Brook Jeang1, John Murad1, Michael O'Leary2
|
1City Of Hope Beckman Research Institute, Duarte, CA, USA 2City Of Hope, Duarte, CA, USA
|
Adoptive immunotherapy | Tumor antigens | Targeted therapy | T cell | CAR T cells | Solid tumors
|
|
P193
|
TRuC™-T Cells: A novel Class of Engineered T cells that Power T Cells through the Entire T Cell Receptor Complex without MHC Restriction
|
Ekta Patel1, Jian Ding1, Nicolaus Thorausch2, Bonnie Lee1, Rashmi Choudhary1, Olga Kiner1, Janani Krishnamurthy1, Justin Quinn1, Patrick Tavares1, Qi Wei1, Solly Weiler1, Wolfgang Schamel2, Patrick Baeuerle1, Robert Hofmeister1
|
1TCR2 Therapeutics, Cambridge, MA, USA 2University of Freiburg, Freiburg, Germany
|
Adoptive immunotherapy | T cell | Solid tumors | CAR T cells | Leukemia/Lymphoma
|
|
P194
|
Studies of Key Quality Attributes for TIL Product, LN-144
|
Krit Ritthipichai1, Ian Frank1, Marcus Machin1, Michelle Simpson-Abelson1, Michelle Blaskovich1, Amanda Stramer1, Michael Lotze1
|
1Iovance Biotherapeutics, Inc., Tampa, FL, USA
|
Adoptive immunotherapy | Tumor infiltrating lymphocytes (TILs)
|
|
P195
|
Anti-CD37 chimeric antigen receptor T cells: a new potential therapeutic option for B-cell malignancies
|
Irene Scarfo1, Maria Ormhøj2, Matthew Frigault2, Marcela Maus2
|
1Massachusetts General Hospital, Charlestown, MA, USA 2MGH, Charlestown, MA, USA
|
CAR T cells | Adoptive immunotherapy | Leukemia/Lymphoma | Tumor antigens
|
|
P196
|
FGFR4 specific Chimeric Antigen Receptor (CAR) T cell therapy against Rhabdomyosarcoma
|
Nityashree Shivaprasad1, Marielle Yohe1, Ying Xiong2, Darong Wu2, Peter Azorsa1, Adam Cheuck1, Joon-Yong Chung1, Zhongyu Zhu3, Dimiter Dimitrov3, Stephen Hewitt1, Boro Dropulic2, Dina Schneider2, Rimas Orentas2, Javed Khan1
|
1National Institute of Health, Bethesda, MD, USA 2Lentigen Technology Inc., a Miltenyi Biotech company, Gaithersburg, MD, USA 3National Institute of Health, Frederick, MD, USA
|
Adoptive immunotherapy | Targeted therapy | Tumor antigens | Antibody | CAR T cells | Gene expression | Solid tumors | T cell
|
|
P197
|
Withdrawn
|
|
|
|
|
P198
|
Bispecific Antibody Armed Activated T cells can Target Drug Resistant Pancreatic Cancer Cells and Cancer Stem Like Cells Effectively.
|
Archana Thakur1, Elyse N Tomaszewski2, Lawrence G Lum1
|
1University of Virginia, Charlottesville, VA, USA 2Karmanos Cancer Institute, Detroit, MI, USA
|
Chemotherapy | T cell | Adoptive immunotherapy
|
|
P199
|
IDO1-mediated tryptophan depletion potently inhibits CAR-T functionality as part of a CAR-T driven adaptive immune resistance response in the tumor microenvironment
|
Evan P. Thomas1, Heidi K. Jessup1, Jim Qin1, Alex Baturevych1, Christina Swanson1, Sarah Swenson1, Ken Prentice1, Hyam Levitsky1, Michael Ports1
|
1Juno Therapeutics, Seattle, WA, USA
|
CAR T cells | Tumor microenvironment | Immune suppression
|
|
P200
|
The use of ex-vivo stimulation to generate a neoantigen specific T-cell product for adoptive T-cell therapy
|
Marit M. van Buuren1, Joost H. van den Berg2, Divya Lenkala1, Jessica Kohler1, Renate de Boer2, Ton N.M. Schumacher2, Edward F. Fritsch1, John B.A.G. Haanen2, Richard B. Gaynor1, Matthew J. Goldstein1
|
1Neon Therapeutics, Cambridge, MA, USA 2Netherlands Cancer Institute, Amsterdam, Netherlands
|
Adoptive immunotherapy | Dendritic cell | Neoantigens | T cell
|
|
P201
|
Targeting Heterogeneous Glioblastoma Using Chlorotoxin-redirected CAR-T Cells
|
Dongrui Wang1, Sarah Wright1, Wen-Chung Chang1, Renate Starr1, Xin Yang1, Brenda Aguilar1, Alfonso Brito1, Aniee Sarkissian1, Behnam Badie1, Stephen J Forman1, Michael E Barish1, Christine E Brown1
|
1City of Hope, Duarte, CA, USA
|
Adoptive immunotherapy | Tumor antigens | CAR T cells | T cell
|
|
P202
|
New Therapeutic Approach for Central Nervous System Lymphoma by CD19CAR T Cells
|
Xiuli Wang1, Ryan Urak1, Christian Huynh1, Miriam Walter1, Laura Lim1, Brenda Aguilar1, Alfonso Brito1, Aniee Sarkissian1, Christine Brown1, Lihua Budde1, Leslie Popplewell1, Stephen Forman1
|
1City of Hope National Medical Center, Duarte, CA, USA
|
Adoptive immunotherapy | CAR T cells
|
|
P203
|
A Cryopreserved TIL Product, LN-144, Generated with an Abbreviated Method Suitable for High Throughput Commercial Manufacturing Exhibits Favorable Quality Attributes For Adoptive Cell Transfer
|
Seth Wardell1, Maria Fardis2, Michael T. Lotze1, Ian Frank1, Amanda Stramer1, Jyothi Sethuraman1, James Bender2, Michelle Abelson1, Lavakumar Karyumpudi1
|
1IOVANCE Biotherapeutics Inc., Tampa, FL, USA 2IOVANCE Biotherapeutics Inc., San Carlos, CA, USA
|
Adoptive immunotherapy | T cell lineages | Neoantigens | Clinical study | T cell | Tumor infiltrating lymphocytes (TILs)
|
|
P204
|
Reenergizing the Tumor Infiltrating T cells by Intratumoral Delivery of BCG to Treat Bladder Cancer and Prevent Recurrence
|
Gang Xin1, Gopit Shah2, William See2, Weiguo Cui1
|
1Blood Research Institute, Blood Center of Wisconsin, Milwaukee, WI, USA 2Medical College of Wisconsin, Milwaukee, WI, USA
|
Vaccine | Tumor infiltrating lymphocytes (TILs) | Solid tumors | Adoptive immunotherapy
|
|
P205
|
Chimeric antigen receptor (CAR) T cells incorporating linker and/or transmembrane domains derived from TNFRSF19 demonstrate superior anti-tumor activity
|
Ying Xiong1, Darong Wu1, Boro Dropulic1, Rimas Orentas1, Dina Schneider1
|
1Lentigen Technology Inc., Gaithersburg, MD, USA
|
Adoptive immunotherapy | CAR T cells | Leukemia/Lymphoma
|
|
P206
|
Tumor-penetrating recombinant protein anti-EGFR-iRGD enhance the extravasation and tumor penetration of lymphocytes in gastric cancer
|
Anqing Zhu1, Huizi Sha2, Baorui Liu2
|
1Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China 2The Comprehensive Cancer Centre of Drum Tower Hospital, Nanjing, China
|
Adoptive immunotherapy | Tumor microenvironment | Tumor infiltrating lymphocytes (TILs) | Solid tumors
|